Pfizer Outlicenses PARP Inhibitor To Clovis
This article was originally published in The Pink Sheet Daily
Executive Summary
Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.
You may also be interested in...
Genetic Exposé Of Ovarian Cancer Prompts Radical Rethink Of Trial Design
Whereas Phase III cancer trials are currently randomized and involve hundreds of patients, some experts say small trials with from 20 to 50 patients make more sense for targeted drugs in ovarian cancer, considering the genetic diversity of this already uncommon disease.
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.